Good day, ladies and gentlemen, and welcome to the Q3 2013 Targacept, Inc. Earnings Conference Call. My name is Tracy, and I'll will be your operator for today. [Operator Instructions] As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Dr. Stephen Hill, Targacept's President and Chief Executive Officer. Please proceed, sir.

Thank you, Tracy, and good morning to everybody, and thank you for joining us. And with me this morning, I have Alan Musso, our Chief Financial Officer. First, let me inform you that comments made today may include forward-looking statements made under the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to plans, expectations, objectives or future events, financial results or condition including, for any of our product candidates, the design, scope or other details of clinical trials, the timing for initiation or completion of or for reporting of results from clinical trials or for submission or approval of regulatory filings, target indications or commercial opportunities, as well as AstraZeneca’s development plans for product candidates licensed from us, our cash runway, revenues or expenses, plans, expectations or any other matter that is not historical fact. Actual results may differ materially from those expressed or implied by any forward-looking statements as a result of many factors, including those described under the heading Forward-Looking Statements in our press release from earlier today or in the heading Risk Factors in our most recent Form 10-K or in later filings with the SEC. We caution you not to place undue reliance on any forward-looking statement. Also, any forward-looking statement that is made speaks only as of today and should not be relied upon as representing our views as of any future date. We disclaim any obligation to update any forward-looking statement except as required by applicable law. So with that, once again, we have seen solid progress this quarter in the advancement of promising pipeline of Phase IIb, neuro nicotinic receptor therapeutics, all aimed at addressing unmet patient needs. I'll start by updating briefly each of our clinical programs. As we announced earlier this year, we have now completed patient recruitment in…

Well, thank you, Steve. Let me now briefly highlight our financial results for the third quarter of 2013, which we released earlier today. We ended the third quarter with a balance of $155.1 million in cash and investments. Our net loss was $12.9 million for the third quarter of 2013, compared to a net loss of $7.9 million for the third quarter 2012, the change due primarily to an increase of $3.9 million in research and development expenses. For the 9 months ended September 30, 2013, our net loss was $33.3 million compared to net income of $8.9 million for the corresponding period of 2012, a change of $42.2 million. The change was primarily due to a decrease of $53.3 million in deferred revenue recognition, partially offset by lower research and development expenses of $8.7 million and the non-recurrence in 2013 of restructuring charges incurred in 2012. As we've guided previously, based on our current operating plans, we expect our cash, cash equivalents and investment balance at the end of 2013 to be at least $135 million, and we continue to expect that our current cash resources will be sufficient to meet our operating requirements through at least the end of 2015. And with that, I would like to open up your call for questions.

So, Tracy, we will be happy to take questions now.

[Operator Instructions] And your first question comes from the line of Alan Carr from Needham & Company. Mark Vignola - Needham & Company, LLC, Research Division: This is actually Mark on for Alan. I was wondering if you could give us a updates on how things are going over at AstraZeneca with regards to 1446 and the strategic review?

Yes, not really. It's for them to communicate any progress in that program and we would be secondary communicators of that. So I think that question is best directed to them, and as and when they communicate anything publically, we'll also reiterate that.

[Operator Instructions]

Tracy, is there any further questions?

We have no further questions. So I would now like to turn the call over to Dr. Stephen Hill for closing remarks. Thank you.

Okay, we appreciate everybody being on the call and we also appreciate that everybody's, like we are, waiting with anticipation for the results of the schizophrenic study towards the end of the year, and we certainly look forward to that and keep our hopes high that we will get positive results from that. So we look forward to that and we will share that with you when we have the information available to hand. Thank you again for your attention, and have a good day.